Keymed Biosciences anuncia los datos de un ensayo clínico de Stapokibart para la dermatitis atópica

Posted on by

– Keymed Biosciences anuncia los datos de eficacia y seguridad a largo plazo de un ensayo clínico de fase III de Stapokibart para el tratamiento de la dermatitis atópica de moderada a grave CHENGDU, China, 3 de junio, 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) anunció hoy…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.